We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$846M
AUM Growth
+$95.3M
Cap. Flow
+$37.1M
Cap. Flow %
4.39%
Top 10 Hldgs %
28.99%
Holding
143
New
11
Increased
56
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$7.11M
2
IART icon
Integra LifeSciences
IART
+$6.94M
3
CI icon
Cigna
CI
+$6.83M
4
ALKS icon
Alkermes
ALKS
+$5.7M
5
IQV icon
IQVIA
IQV
+$5.62M

Top Sells

Rank Stock Value
1
AKRX
Akorn Inc
AKRX
+$11.9M
2
CNC icon
Centene
CNC
+$9.33M
3
INCY icon
Incyte
INCY
+$8.09M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$6.18M
5
ALR
Alere Inc
ALR
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 92.73%
2 Financials 0.93%
3 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LIVN icon
51
LivaNova
LIVN
$4.43B
$6.29M 0.74%
102,808
+38,619
+60% +$2.18M
IQV icon
52
IQVIA
IQV
$34.4B
$5.95M 0.7%
+66,520
New +$5.62M
BMRN icon
53
BioMarin Pharmaceuticals
BMRN
$11.5B
$5.9M 0.7%
65,000
– –
ACAD icon
54
Acadia Pharmaceuticals
ACAD
$4.38B
$5.85M 0.69%
186,000
+141,000
+313% +$4.2M
COO icon
55
Cooper Companies
COO
$14B
$5.75M 0.68%
96,000
+16,000
+20% +$869K
MGNX icon
56
MacroGenics
MGNX
$285M
$5.54M 0.66%
316,418
+11,821
+4% +$225K
CERN
57
DELISTED
Cerner Corp
CERN
$4.95M 0.59%
74,500
– –
HZNP
58
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.84M 0.57%
407,398
-91,367
-18% -$1.14M
GNMK
59
DELISTED
GenMark Diagnostics, Inc
GNMK
$4.79M 0.57%
405,178
+92,512
+30% +$1.18M
JNJ icon
60
Johnson & Johnson
JNJ
$609B
$4.17M 0.49%
31,500
– –
CBPO
61
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$4.1M 0.48%
+36,250
New +$4.05M
XRAY icon
62
Dentsply Sirona
XRAY
$2.81B
$3.27M 0.39%
50,500
+5,500
+12% +$347K
ESRX
63
DELISTED
Express Scripts Holding Company
ESRX
$3.16M 0.37%
49,500
– –
MCK icon
64
McKesson
MCK
$98.5B
$2.96M 0.35%
18,000
-6,000
-25% -$910K
IPXL
65
DELISTED
Impax Laboratories, Inc.
IPXL
$2.82M 0.33%
+175,000
New +$2.59M
RMD icon
66
ResMed
RMD
$28.9B
$2.81M 0.33%
36,100
+28,100
+351% +$2.01M
HALO icon
67
Halozyme
HALO
$9.23B
$2.81M 0.33%
219,000
-51,000
-19% -$681K
XENT
68
DELISTED
Intersect ENT, Inc
XENT
$2.79M 0.33%
100,000
– –
DXCM icon
69
DexCom
DXCM
$29.6B
$2.74M 0.32%
150,000
+5,600
+4% +$103K
NUVA
70
DELISTED
NuVasive, Inc.
NUVA
$2.72M 0.32%
35,304
+4,000
+13% +$299K
CVS icon
71
CVS Health
CVS
$137B
$2.69M 0.32%
33,400
– –
QGEN icon
72
Qiagen
QGEN
$8.49B
$2.66M 0.32%
+74,920
New +$2.53M
TSRO
73
DELISTED
TESARO, Inc.
TSRO
$2.66M 0.31%
19,000
+3,000
+19% +$434K
TMO icon
74
Thermo Fisher Scientific
TMO
$198B
$2.55M 0.3%
14,600
+1,600
+12% +$269K
BLUE
75
DELISTED
bluebird bio
BLUE
$2.32M 0.27%
1,706
-533
-24% -$643K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2017 Portfolio in Review

As of Q2 2017, Bellevue Group held 143 positions worth $846M, up 13% from $750M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $37.1M of net new capital in Q2 2017, opening 11 new positions and adding to 56 existing holdings. Its largest new stake was IQVIA: 66,520 shares worth $5.95M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Centene, an estimated $9.33M trimmed.

  • Bellevue Group's largest Q2 2017 buy was IQVIA: 66,520 shares worth $5.95M.
  • Bellevue Group added most to Edwards Lifesciences in Q2 2017, an estimated $7.11M increase.
  • Bellevue Group's biggest Q2 2017 reduction was Centene, cutting an estimated $9.33M.
  • Bellevue Group fully exited Akorn Inc in Q2 2017, selling an estimated $11.9M.
  • Bellevue Group's ten largest holdings make up 29% of its $846M portfolio in Q2 2017.
  • Bellevue Group opened 11 new positions and closed 11 in Q2 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $846M.

Based on Bellevue Group's 13F filing for Q2 2017, filed 14 Aug 2017.